ATS Pulmonary Function Laboratory Manual

cHAPTER 7

References 1. Dales RE, Spitzer WO, Tousignant P, Schechter M, Suissa S. Clinical interpretation of airway response to bronchodilator testing: epidemiologic considerations. Am Rev Respir Dis 1988;138: 317–320. 2. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al . Standardisation of spirometry. Eur Respir J 2005;26:319–338. 3. Casaburi R, Adame D, Hong CK. Comparison of albuterol to isoproterenol as a bronchodilator for use in pulmonary function testing. Chest 1991;100:1597–1600. 4. Newman SP. Aerosol generators and delivery systems. Respir Care 1991;36:939–951. 5. Dolovich M, Ruffin RE, Roberts R, Newhouse MT. Optimal delivery of aerosols from metered dose inhalers. Chest 1981;80:911–915. 6. American Association for Respiratory Care Clinical Practice Guideline. Selection of a device for delivery of aerosol to the lung parenchyma. Respir Care 1996;41:647–653. 7. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, et al . Interpretative strategies for lung function tests. Eur Respir J 2005;26:948–968. 8. Boggs PB, Khat KD, Vekovius WA, Debo MS. The clinical significance of volume adjusted maximal mid expiratory flow (iso-volume FEF 25-75% ) in assessing airway responsiveness to inhaled bronchodi- lators in asthmatics. Ann Allergy 1982;48:139–142. 9. Mendella LA, Manfreda J, Warren CPW, Anthonisen NR. Steroid response in stable chronic obstruc- tive pulmonary disease. Ann Intern Med 1982;96:17–21. 10. Tweeddale PM, Alexander F, McHardy GJR. Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax 1987;42:487–490. 11. Brand PL, Quanjer PH, Postma DS, Kerstjens HA, Koëter GH, Dekhuijzen PN, Sluiter HJ. Interpre- tation of bronchodilator response in patients with obstructive airway disease. The Dutch Chronic Non-specific Lung Disease (CNSLD) Study Group. Thorax 1992;47:429–436. 12. Boggs PB, Khat KD, Vekovius WA, Debo MS. The clinical significance of volume adjusted maximal mid expiratory flow (iso-volume FEF 25-75% ) in assessing airway responsiveness to inhaled bronchodi- lators in asthmatics. Ann Allergy 1982;48:139–142. 13. Mendella LA, Manfreda J, Warren CPW, Anthonisen NR. Steroid response in stable chronic obstruc- tive pulmonary disease. Ann Intern Med 1982;96:17–21. 14. Peters SP, Bleecker ER, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, Boushey HA, Calhoun WJ, Castro M, et al . Predictors of response to tiotropium versus salmeterol in asthmatic adults. J Allergy Clin Immunol 2013;132:1068–1074. 15. Tweeddale PM, Alexander F, McHardy GJR. Short term variability in FEV 1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax 1987;42:487–490. 16. Quanjer PH, Weiner DJ, Prieto JJ, Brazzale DJ, Boros PW. Measurement of FEF 25-75% and FEF 75% does not contribute to clinical decision making. Eur Respir J 2014;43:1051–1058.

71